GlassScriptPhysician profile
David J Gomeringer
NPI 1043236755
$1,936.39
in general payments reported to CMS, 2019-2025
27 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $451 · 2021: $244 · 2022: $126 · 2023: $106 · 2024: $145 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $315.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $264.74 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $246.21 | 2019-2021 | |
| Lilly USA, LLC | $227.07 | 2019-2022 | |
| Pfizer INC. | $118.03 | 2019-2025 | |
| Esperion Therapeutics, INC. | $116.29 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $88.28 | 2019-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $85.51 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $56.55 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $49.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.46 | 2021-2022 | |
| Inspire Medical Systems, INC. | $41.27 | 2025 | Inspire |
| Almatica Pharma LLC | $32.97 | 2021-2022 | |
| Nevro Corp. | $28.86 | 2024 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.71 | 2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.67 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $20.93 | 2019 | |
| Genentech USA, INC. | $19.19 | 2021 | |
| Horizon Therapeutics Plc | $17.40 | 2020 | |
| Shire North American Group INC | $17.28 | 2019 | |
| Allergan, INC. | $15.28 | 2020 | |
| Medicure Pharma INC. | $15.18 | 2021 | |
| Organogenesis INC. | $14.83 | 2020 | |
| Currax Pharmaceuticals LLC | $14.73 | 2022 | |
| Abbvie INC. | $13.76 | 2021 | |
| Adlon Therapeutics L.P. | $13.05 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gomeringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.